Trial Profile
Evaluation of the anti-anginal efficacy and safety of oral administration of ivabradine compared to placebo on top of background therapy with atenolol in patients with stable angina pectoris. A four-month randomised double-blind, parallel group international multicentre study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Jan 2022
Price :
$35
*
At a glance
- Drugs Ivabradine (Primary) ; Atenolol
- Indications Angina pectoris; Coronary artery disease
- Focus Therapeutic Use
- Acronyms ASSOCIATE
- Sponsors IRIS
- 15 Jun 2011 Actual end date (Oct 2007) added as reported by ClinicalTrials.gov.
- 30 Aug 2008 Endpoint 'Time to exercise induced ECG change' has been met (results reported at ESC 2008).
- 30 Aug 2008 Endpoint 'Time to exercise induced angina pectoris' has been met (results reported at ESC 2008).